Threshold Pharmaceuticals (THLD)

Business description

Threshold is focused on tumour hypoxia, a low-oxygen condition found in most solid tumours and some blood cancers. Evofosfamide is in Ph III for STS and pancreatic cancer and earlier trials in other cancers. It is partnered with Merck KGaA.

Further encouraging data at ASCO

QuickView | Pharmaceutical & healthcare | 11/06/2014

Updated and detailed TH-302 Phase I/II glioblastoma (GBM) and Phase I/II multiple myeloma (MM) data were presented at ASCO, with investigators highlighting the early signals of clinical activity in each of these indications. Both of these disease settings could potentially be eligible for accelerated development, given the unmet medical need, with seemingly limited value ascribed to either at current levels.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.US$35.6m
Last closeUS$0.498
High / Low (52 weeks)US$1.3 / US$0.4
Stock market listingUS
Forecast net cash (US$m)31
Forecast gearing ratio (%)N/A
SectorPharmaceutical & healthcare

Price performance

Relative *24.2(4.6)(14.3)

* % Relative to local index

Company news

Threshold Pharmaceuticals

Thu, 15 Mar 2018 12:00:00 GMT

Threshold Pharmaceuticals

Fri, 02 Mar 2018 21:22:30 GMT

Threshold Pharmaceuticals

Thu, 03 Aug 2017 13:14:12 GMT

Threshold Pharmaceuticals

Mon, 20 Mar 2017 13:41:15 GMT

Threshold Pharmaceuticals

Fri, 17 Mar 2017 10:52:30 GMT